Liposomal Irinotecan, 5-fluorouracil/Calcium Folinate, Oxaliplatin, and Adebrelimab in Combination With Radiotherapy for Resectable or Borderline Resectable Pancreatic Cancer With Risk Factors：A Prospective Exploratory Study

NCT07542002 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

37

Enrollment

OTHER_GOV

Sponsor class

Conditions

Pancreatic Cancer

Interventions

DRUG: Irinotecan liposome, 5-fluorouracil/leucovorin, and oxaliplatin, with or without adadelimab.

Sponsor

Ningbo Medical Center Lihuili Hospital